SBIR Phase I: Development of an Allergen-Reduced Peanut for Commercialization

SBIR 第一阶段：开发用于商业化的低过敏原花生

• 批准号: 1620897
• 负责人: Hortense Dodo
• 金额: $ 22.5万
• 依托单位: IngateyGen LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1620897&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; Allergen; Reduced

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project will be to produce and commercialize an allergen-reduced peanut. The goals are to: 1) save human lives by preventing allergy-related deaths, 2) reduce the incidence of peanut allergy, 3) increase security, comfort and peace of mind for those individuals sensitive to peanuts and their families, friends, schools, and restaurants, 4) reduce and/or eliminate the number of institutional lawsuits resulting from peanut allergy events, 5) reduce and/or eliminate the number of expensive food recalls due to peanut contaminations, 6) gain back the loss endured by the peanut market, and improve the U.S. competitive edge on the international peanut market, and 7) increase sales by 15% to 20% due to an increase market by restaurants, airlines and more. Food allergies cost the US $25 billion annually and peanut is a major contributor. The proposed allergen-reduced peanut may provide a significant solution to peanut allergy with the potential to reduce the overall cost of food allergy. This SBIR Phase I project proposes to produce a commercial prototype for an allergen-reduced peanut. In previous works, concomitant down regulation of the 3 most potent allergens Ara h1, Ara h2 and Ara h3 was demonstrated and resulted in 2 to 25 fold reduction in allergenic potency. The allergen-reduced trait was transmitted to four successive generations in the progeny in field trials. However, the populations of transgenic seeds were not homogeneous; they displayed variable levels of allergenic potency among pods from the same plant. To solve this problem, an alternative transformation method based on Repetitive Somatic Embryogenesis is proposed to produce new sets of transgenic peanut plants devoid of chimerism. During this Phase I project, molecular, biochemical and immunological analyses will be performed to confirm the new sets of transgenic peanut plant lines are chimera-free, and a commercial prototype for the allergen-reduced peanut will be identified.

这个小企业创新研究（SBIR）项目的更广泛的影响/商业潜力将是生产和商业化的过敏原减少花生。 目标是：1）通过预防过敏相关的死亡来拯救人类生命，2）减少花生过敏的发生率，3）增加对花生敏感的那些个体及其家人、朋友、学校和餐馆的安全性、舒适性和心灵的平静，4）减少和/或消除由花生过敏事件引起的机构诉讼的数量，5）减少和/或消除因花生污染而召回的昂贵食品的数量，6）挽回花生市场遭受的损失，并提高美国在国际花生市场上的竞争优势，7）由于餐馆、航空公司等市场的增长，销售额增加15%至20%。食物过敏每年花费250亿美元，花生是主要贡献者。所提出的减少过敏原的花生可以提供花生过敏的重要解决方案，具有降低食物过敏的总成本的潜力。 SBIR第一阶段项目提出生产一种减少过敏原的花生的商业原型。在先前的工作中，证实了3种最有效的变应原Ara h1、Ara h2和Ara h3的伴随下调，并导致变应原效力降低2至25倍。在田间试验中，变应原减少的性状在后代中连续传递到四代。然而，转基因种子的群体是不均匀的，他们显示出不同水平的过敏性效力之间的豆荚从同一植物。为了解决这个问题，提出了一种基于重复体细胞胚胎发生的替代转化方法，以产生新的转基因花生植株。在第一阶段项目期间，将进行分子、生物化学和免疫学分析，以确认新的转基因花生植物系是无嵌合体的，并将确定减少过敏原的花生的商业原型。